TSX:FRX - Toronto Stock Exchange - CA31447P1009 - Common Stock - Currency: CAD
TSX:FRX (7/17/2025, 7:00:00 PM)
11.98
+0.31 (+2.66%)
The current stock price of FRX.CA is 11.98 CAD. In the past month the price increased by 5.64%. In the past year, price increased by 42.28%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
EPRX.CA | EUPRAXIA PHARMACEUTICALS INC | N/A | 267.18M | ||
EDT.CA | SPECTRAL MEDICAL INC | N/A | 231.27M | ||
TH.CA | THERATECHNOLOGIES INC | N/A | 198.63M | ||
ONC.CA | ONCOLYTICS BIOTECH INC | N/A | 158.10M | ||
WLLW.CA | WILLOW BIOSCIENCES INC | N/A | 144.77M | ||
HBP.CA | HELIX BIOPHARMA CORP | N/A | 74.16M | ||
MDNA.CA | MEDICENNA THERAPEUTICS CORP | N/A | 73.37M | ||
COV.CA | COVALON TECHNOLOGIES LTD | 19.92 | 71.02M | ||
MSCL.CA | SATELLOS BIOSCIENCE INC | N/A | 58.20M | ||
BLU.CA | BLUENERGIES LTD | N/A | 55.79M | ||
SVA.CA | SERNOVA BIOTHERAPEUTICS INC | N/A | 41.96M | ||
MBX.CA | MICROBIX BIOSYSTEMS INC | 29.5 | 41.47M |
Fennec Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company is headquartered in Research Triangle Park, North Carolina. The company went IPO on 2001-06-05. The company sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is an approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. The company is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase III clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. The company has established Fennec HEARS, a single source program designed to connect PEDMARK patients.
FENNEC PHARMACEUTICALS INC
PO Box 13628, 68 Tw Alexander Dr
RESEARCH TRIANGLE PARK NORTH CAROLINA 27709 US
CEO: Rostislav Raykov
Employees: 36
Phone: 19196364530
The current stock price of FRX.CA is 11.98 CAD. The price increased by 2.66% in the last trading session.
The exchange symbol of FENNEC PHARMACEUTICALS INC is FRX and it is listed on the Toronto Stock Exchange exchange.
FRX.CA stock is listed on the Toronto Stock Exchange exchange.
11 analysts have analysed FRX.CA and the average price target is 17.71 CAD. This implies a price increase of 47.8% is expected in the next year compared to the current price of 11.98. Check the FENNEC PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
FENNEC PHARMACEUTICALS INC (FRX.CA) has a market capitalization of 330.89M CAD. This makes FRX.CA a Small Cap stock.
FENNEC PHARMACEUTICALS INC (FRX.CA) currently has 36 employees.
FENNEC PHARMACEUTICALS INC (FRX.CA) has a support level at 10.9 and a resistance level at 12.17. Check the full technical report for a detailed analysis of FRX.CA support and resistance levels.
The Revenue of FENNEC PHARMACEUTICALS INC (FRX.CA) is expected to decline by -16.58% in the next year. Check the estimates tab for more information on the FRX.CA EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
FRX.CA does not pay a dividend.
FENNEC PHARMACEUTICALS INC (FRX.CA) will report earnings on 2025-08-07, before the market open.
FENNEC PHARMACEUTICALS INC (FRX.CA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.7).
ChartMill assigns a technical rating of 9 / 10 to FRX.CA. When comparing the yearly performance of all stocks, FRX.CA is one of the better performing stocks in the market, outperforming 87.81% of all stocks.
ChartMill assigns a fundamental rating of 3 / 10 to FRX.CA. While FRX.CA seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months FRX.CA reported a non-GAAP Earnings per Share(EPS) of -0.7. The EPS decreased by -666.67% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -31.11% | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 85% to FRX.CA. The Buy consensus is the average rating of analysts ratings from 11 analysts.
For the next year, analysts expect an EPS growth of 308694732858483400% and a revenue growth -16.58% for FRX.CA